StockpollyBeta
Get App
Delisting riskPopularity #5,333
KPRX · NASDAQ · Biotechnology

Kiora Pharmaceuticals (KPRX)

Develops intravitreal photoswitch and DHODH-inhibitor candidates for retinal degeneration and inflammation.

$2.76
After hours+0.02 (+0.73%)
At close$2.74(+2.24%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0016000000000
Cost of revenue0—0000000000
Gross profit0—16000000000
623343221722
Research & development112111111122
111211111121
General & administrative101211111121
Other expenses30001000−25−1−1
Operating income−6−213−3−4−3−2−2−1−7−3−2
000000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income−3000−10002−200
Income before tax−6−213−2−3−2−2−2−1−7−2−2
Income tax expense00000200−1−100
Net income from continuing operations−6−213−2−3−4−2−20−7−2−2
Net income−6−213−2−3−4−2−20−7−2−2
EPS, basic−$0.81−$0.29$4.67−$0.53−$0.81−$1.41−$0.52−$0.54$0.01−$1.59−$0.58−$0.34
EPS, diluted−$0.81−$0.29$3.46−$0.53−$0.81−$1.41−$0.52−$0.54$0.01−$1.59−$0.58−$0.34
Weighted average shares, basic7826443444446
Weighted average shares, diluted7835443444446
EBITDA−2−213−2−3−2−2−2−3−5−2−2
Depreciation & amortization0—0000000000
EBIT−3−213−2−3−2−2−2−3−5−2−2